Camp4 Therapeutics Corp (CAMP) Form 8-K — Aug 13, 2026
CAMP4 Therapeutics reported a second-quarter 2026 net loss of $33.5 million, up sharply from $12.6 million a year earlier, driven by a $20.9 million non-cash loss from the change in fair value of a derivative tranche liability tied to its September 2025 private placement. Cash and cash equivalents stood at $86.4 million at June 30, 2026, versus $109.5 million at year-end 2025. After quarter-end, the company received $50.1 million in gross proceeds from a fully subscribed second closing of its private placement, extending its cash runway through the end of 2028.
Key figures
- Revenue
- 1779000
- Revenue Yoy
- +18.8% YoY ($1.779M vs $1.497M research and collaboration revenue)
- Total Assets
- 93428000
- Cash Position
- 86398000
- Cash Runway
- through end of 2028
- Analyst Day Date
- September 28, 2026
- Working Capital
- $70.9M (June 30, 2026) vs $98.6M (December 31, 2025)
- Ga Expense Q2 2026
- $4.3M vs $4.2M (Q2 2025)
- Net Loss Prior Year
- $12.6M (Q2 2025)
- Rd Expense Q2 2026
- $10.8M vs $10.3M (Q2 2025)
- Total Liabilities
- $94.1M (June 30, 2026)
- Accumulated Deficit
- $344.0M
- Stockholders Deficit
- -$0.7M (June 30, 2026) vs $47.7M equity (December 31, 2025)
- Clinical Trial Launch Target
- Q4 2026
- Weighted Average Shares Q2 2026
- 57929662
- Derivative Tranche Liability Fair Value Loss
- $20.9M non-cash (Q2 2026)
- Private Placement First Closing Gross Proceeds
- ~$50M (September 2025)
- Private Placement Second Closing Gross Proceeds
- $50.1M (post quarter-end)
Price after filing
Close on the filing date to close N calendar days later (from $4.50). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.